The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …

Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly
supplanting long-established traditional cell lines as preferred models for conducting basic …

Estrogen and progesterone receptor (ER, PR) signaling control breast development and
impinge on breast carcinogenesis. ER is an established driver of ER+ disease but the role of …

Although mutations leading to a compromised nuclear envelope cause diseases such as
muscular dystrophies or accelerated aging, the consequences of mechanically induced …

Ductal carcinoma in situ (DCIS) is an intraductal neoplastic proliferation of epithelial cells
that is separated from the breast stroma by an intact layer of basement membrane and …

Research using animal model systems has been instrumental in delivering improved
therapies for breast cancer, as well as in generating new insights into the mechanisms that …

A mounting body of evidence in cancer research suggests that the local microenvironment of
tumor cells has a profound influence on cancer progression and metastasis. In vitro studies …

The biguanide metformin, a widely used drug for the treatment of type 2 diabetes, may exert
cancer chemopreventive effects by suppressing the transformative and hyperproliferative …

Seventy-five percent of breast cancers are estrogen receptor α positive (ER+). Research on
these tumors is hampered by lack of adequate in vivo models; cell line xenografts require …

New cancer therapies are likely to arise from an in-depth understanding of the signaling
networks influencing tumor initiation, progression and metastasis. We show a fundamental …